[shell3]

Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Receives-Notice-of-Intention-to-Grant-from-Chinese-Patent-Office-for-Repirinast-to-Treat-NASH-a?id=423123

[tcm55]

Seems to be lots of talk about PTSD - TBI - in the Veteran communities from well respected folks for the use of shrooms and/or CBD. I think this could encompass the stroke recovery research use of psylocibin that our company is trying to move forward and of course a new/large group of patients in need.
It's not over and this latest possible deal may help finance more AGN work. I hope they are talking to some of the Veteran groups that are interested and active in this...
...GLTA...

[Max2121]

This is exactly what I was talking about.

“Only thing I can find one page as web page which explains todays news, lol.
It seems it is a new web page set up for this news”.

Just my opinion.

[smoki]

https://seyltx.com/about/ that’s it! Lol again…

[Max2121]

Yes,

Seyltx is a U.S.-based Delaware C-corporation

[McMagyar]

News release gave city in USA

[Max2121]

Interesting to search…

No contact info about Seyltx from news release from Algernon today and no web page as well.

One would think anybody spend $2 mil with with 20, would have contact info.

Googled Seyltx.

Only thing I can find one page as web page which explains todays news, lol.
It seems it is a new web page set up for this news.
Is it possible? Of course, I can be wrong here.

Is there a way to find out anything about Seyltx,

who owns it?
Where is located?
Established year?
Contact names(real)?

[McMagyar]

Propanc has a Caesar share that votes the only vote that counts
Don’t know how it’s legal but I guess if you tell people your screwing rhem before it’s ok

[Max2121]

I am not familiar with those cos & news.

How the scam took place, by whom, parties?

Can you enlighten us with more details?

Or their news and posts?

I will appreciate your input. It is good to know.

[McMagyar]

I have seen this before with po
Ppcb.. but that IS a scam with a Caesar share..
Under capitalized BioPharm is what it is

[Max2121]

I hope you are right and I am wrong.

However, I have different opinion about C.Moreau.
——

Here is his leadership team.
Look into R/S history, since he has been running the company.
How many times R/S took place?

Look into company’s capitalization. Has he reduced his remuneration while shareholders were bleeding & burning?
——-
No wonder, they have only consultants.
Can they afford other employees with those salaries?
——-

Leadership Team


Christopher Moreau
CEO & Director

CA$576.45k

James Kinley
Chief Financial Officer

CA$170.04k

Christopher Bryan
Vice President of Research & Operations

CA$257.54k

Note:
Accuracy of this team members and salaries cannot be verified. Please do your own proper DD‘s and know your risk tolerance.

Just my opinion I am not recommending. buy, sell or hold.

It is just my opinion. Good luck to all.

[McMagyar]

Understood Max
The small base of current shareholders
are NOT going to fund it’s future.
Chris is going to need a new Management team that attracts Capital..

But he bought himself time with this sale..

And Time is a precious thing..

Don’t think overhead quarterly burn very high with no Clinicals in process..
Our Neuro holding doesn’t have expense attached nor our new proposed holding..

Someone posted that all staff are now consultants..
I simply don’t know enough about reprinast..

I would turn to Neuro advantage..
Let’s find a way to make money with Neuro success..either by marketing support or equipment supply..

Let’s look at ambulatory care for stroke victims .. what will Neuro need for rapid test to determine stroke type?
What will Neuro need for immediate dosing?

It’s OUR subsidiary! Let’s use it

[Max2121]

$ 2 mil in the bank?

How much are they burning cash a month?

How about overhead payments, research development, etc.

Any other loans to pay ?

Obvious that they could not raise cash any longer from depleted shareholders ?

burn too many times with this stock ?

do your own DD it’s just my opinion .

[McMagyar]

I also want to say..

Although this may not bring the market cap of agnpf up.. it certainly is a good start to a new trusting process

[McMagyar]

So 15,000,000 shares at 5 cents puts us at
750,000
With $2,000,000 in bank and 20% equity in ? I have no idea how big private drug co is.. but imagine they would go public or sell with ilfenprodil approval..
we would get 20% of a lot..
ilfenprodil works..I can testify


Maybe Chria can figure out a way
For algernon to partner with algernon Neuro..maybe we can have the marketing rights to DMT for North America..?

Maybe algernon can buy an emergency supplier of Mobile IV kit that algernon Neuro uses..

Now we have cash let’s create a cash flow

[shell3]

Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-for-?id=422342

[shell3]

9. Report on any employee hiring’s, terminations or lay-offs with details of anticipated length of lay-offs.

As part of the Company’s efforts to conserve capital, the Company terminated its employment agreements with its employees, however the company continues to operate with its personnel under consulting agreements beginning as of October 1, 2023.

[shell3]

Outstanding: 15,775,757 posted for October 6, 2023

Monthly 5th Report

https://webfiles.thecse.com/9._Algernon_-_CSE_Form_7_-_September_2023.pdf?_2Td4NbezBWyKX3PFrcNh8_oS1KYN5WP

[McMagyar]

I think Moreau is an honorable man
I don’t think anyone trying to swindle the DMT asset from out underneath agnpf

The problem is .. I don’t think management owns very much stock..
There are no golden handcuffs so to speak.

We should change that either by option or Chria could change that by purchase or both..

[tcm55]

AGN needs to publish the CHDR DMT peer review, or/and,
AGN needs to sell their IPF/CC trial results and Ifenprodil rights,
these should get the phase 2 of the Microdose DMT / stroke trial started which is the real possible success story here.
All investors in this speculative stock would be real happy for some good overdue news. Many would then show support with some further investments
...IMHFO...
...GLTA...

[smoki]

Management’s not encouraging anyone to buy their stock … what does that tell you…

[McMagyar]

Prove me wrong ..
I want to buy more and apologize

[McMagyar]

So our $15,000,000 asset is valued
at $1.5 million..

Something isn’t right

[McMagyar]

If I had to guess..
algernon neuroscience is going to buy out its 60-% ownerahip from algernon for a pittance..

Or maybe algernon will go bankrupt and someone will get “lucky” buying the 60% of algernon neuroscience.

This valuation makes zero sense


Zero

Very frustrating

I would buy the heck out of this
if management were doing the same

[McMagyar]

I just font understand.. insiders have to know the mi no I’m I’m value for this asset:
60% algernon Neuro
Repurpose Patent
Repurpose cough

No money

Is north of $15m

It just smells awful down here at $.10
Like somebody knows something I don’t

[McMagyar]

The patent is worth $10 m by itself..
does anybody trust Moreau?

[shell3]

Outstanding: 15,775,757 posted for September 8, 2023

Monthly 5th Report

https://webfiles.thecse.com/8._Algernon_-_CSE_Form_7_-_August_2023.pdf?pZ8C.CRdKLA.5xm56A9TAhWNIMThwzv8

[Max2121]

I did not exercise, sold the warrants.

I was following the company very closely as a shareholder and I was very positive about the outlook of Algernon.

C. J. Moreau burned to many times shareholders. I have lost complete trust in him. I am sure I am not the only one

He played too many games with shareholder, such as how he advertised and we got sucked in, I know it and I have the copes of his PRs.

Don’t ask about issued warrants to USA shareholders, it was late a week and some sold them early prior other shareholders had warrants in their accounts.

They got the patent today, but look at the stock… no liquidity, no interest to buy.

Why?

Because to many promises he has made and never delivered anything that shareholders could benefit.

The stock should have been .30 to .50 today with this news. Look at it where it is.

Moreau need miracles or extra ordinary news development to get back shareholders trust him again. Having YouTube videos as PR are not helping him.

We know who has benefiting from his actions, not shareholders.

The best thing for Algernon will be Moreau resigns and they can replace him with someone who knows what he is doing not just talk and promises.

[shell3]

Having Patent give them leverage for hopefully Money jump- in verse Last Shares Sold was for .20 CAD or .15 AGNPF with .25 CAD Warrants

And there’s not enough Cash-On-Hand to finish the Quarter and need another $200,000 to finish Quarter - JMO

1,000,000 x $0.20 is $200,000

[smoki]

What happens going forward after patent granted … anyone?

[smoki]

Great news!!!

[shell3]

Grant of U.S. Patent for Repirinast in NAFLD and NASH[/b[

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Grant-of-US-Patent-for-Repirinast-in-NAFLD-and-NASH?id=413131

[McMagyar]

Myself as well..
the microdosing for stroke is very exciting

[tcm55]

Yes! smoki... That is the strong Ifenprodil research data that apparently AGN is now trying to sell (or still to gather a sponsor?) instead of running the 180 patient CT itself.
Thanks for reposting this news so we can all see the strong results and P values AGN saw during that 2a CT, as a "Secondary" side set of data that was originally for COVID/Long COVID.
It would be too expensive to do both the DMT Microdose for Stroke and this follow on for Ifenprodil CC/IPF. I agree with the DMT path and selling the "rights " for the CC/IPF Ifenprodil research to move that one forward, asap,...JMHO...
...GLTA...

[smoki]

https://www.globenewswire.com/en/news-release/2023/01/09/2585006/0/en/Algernon-Pharmaceuticals-Announces-Plans-for-a-180-Patient-Phase-2b-Chronic-Cough-Study-of-Ifenprodil.html

[McMagyar]

Phase 2
40 patients
Find a stroke -not for profit - to help fund

Biometric of neuronal cell growth
and patient improvement ..

Means the pathway is multi billions..

Chris just tell us how you will reward
Agnpf shareholders with success.

Thx

[McMagyar]

The perhaps part should be spelled out.
Look.. I believ this is a brilliant move with DMT ..
really I do..
I bet I can do a Google in DMT and feel confident that DMT is going to kick some serious CNS malfunctions..

What do we benefit? Owning 50% of a billion dollar co does NOT mean you are worth $600 million..

It doesn’t..

Spell it out .. thx

[tcm55]

Remember that the DMT Phase 1 was to determine "sub psychedelic dose levels". AGN had also paid for specific neuro marker tests that should help prove ' MOU/ proof of concept' for the upcoming Phase 2 CT, which is/has been planned now.
I sure hope that phase 2 data from the Ifenprodil CT will help find a buyer as that data is as strong as any drug's for IPF/CC. This should be enough to finance the next steps for DMT, possible even the whols Phase 2 CT. I bet this is 'of course' the main focus for Mr Monroue.
The peer data from DMT should also be released soon.
As 60% owners of AGN-Neuro we are financing all this and at the least will see proportional benefits, maybe even the dividends you mentioned. JMHO.
...GLTA...

[GVX808]

Good discussion by tcm and McM.
100% agree with you both.

It’s looking pretty grim, but I’m always down for a last minute Hail Mary.

I’m not convinced Moreau won’t screw shareholders in the end, but who knows… maybe Algernon will surprise us all.

Ifenprodil seems to have great potential.
The fact that Ivermectin is now suddenly being widely accepted as a treatment for COVID certainly makes you question everything within the realm of pharma.

[McMagyar]

Why wouldn’t you do no psych dose to grow neurons?
I think dementia patients will be talking this treatment .

The bigger factor is

many Canadian companies treat
their companies like club Canada..
They make sure Canadians win
and really everyone else is a second class.

I get that for protecting ownership in Canadian hands.. us should do a better job.

Personally I would like to see
a forward plan..
Of what happens WHEN we are successful?

Do we get dividends?
We own 60% of algernon Neuro but what does that mean?

I think this is a winner..
but have seen winners be losers for
common shareholders and not leadership..

So I love the product
Love the opportunity
Like Chris and his leadership..
Could absolutely go much deeper investment wise if I understood

How all investors will win when this becomes a blockbuster drug..

Why wouldn’t the neuroscience people just invest in algernon?

Is algernon going to dividend the 60% of neuroscience to shareholders?


Holding companies May languish for very long periods of time

[tcm55]

Stroke is like cancer, IMO. There will be plenty of folks willing to try anything to help. Most cancer drugs are $10k a treatment / dose ( Ketruda/Optivo) and some were $70k a dose (Yeravoy).
So basically I see the stroke treatment is doctor supervision costs and the DMT probably will be much less per dose. Certainly a large patient population that needs something.
Sure hope they can sell their/our work and rights from the Ifenprodil Clinical Trials, CC/IPF, to help finance this. Seemed a viable alternative to the other much more expensive drugs with about equal results...
...GLTA...

[smoki]

Don’t think they’re going to make it at this point … who’s going to give them the right to Ginny pig a patient that just had a stroke…not making since imo

[shell3]

Outstanding: 15,775,757 posted for August 8, 2023

Monthly 5th Report

https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July_2023.pdf?zwGrUHYlGcXfmUGKGAi9jEkDIHCkOide

[shell3]

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Announces-40-Patient-Phase-2-Psychedelic-Drug-DMT-Stroke-Study?id=410020

[shell3]

13. SUBSEQUENT EVENTS

Subsequent to May 31, 2023


On July 26, 2023, the Company issued to Maxim Group LLC (“Maxim”) 200,000 common shares at a deemed issue price of $0.22, being the closing price of the common shares on the CSE on July 13, 2023, as initial compensation for entering into an engagement letter (the “Engagement Letter”) pursuant to which Maxim will provide financial advisory and investment banking services, and assist in identifying and evaluating potential M&A and strategic opportunities, including the potential spin-off of the Company's Ifenprodil chronic cough research program. In connection with entering into the Engagement Letter, the Company may be obligated to issue up to an additional 200,000 Common Shares to Maxim in certain circumstances. The Company may also be obligated to pay Maxim a success fee upon the consummation of a successful transaction.

On July 27, 2023, the Company closed a non-brokered private placement for gross proceeds of $205,000 (the “Offering”) of units (the “July 2023 Units”) at an issue price of $0.20 per July 2023 Unit. Each July 2023 Unit will consist of one common share in the capital of the Company and one common share purchase warrant (a “July 2023 Warrant”). Each July 2023 Warrant will entitle the holder to acquire one common share (a “July 2023 Warrant Share”) at an exercise price of $0.25 per July 2023 Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below.

The July 2023 Warrants are subject to accelerated expiry in the event the volume weighted average trading price of the common shares exceeds $0.50 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the July 2023 Warrants accelerating the Expiry Date of the July 2023 Warrants to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the “Accelerated Exercise Period”). Any unexercised July 2023 Warrants shall automatically expire at the end of the Accelerated Exercise Period. The Company will use the proceeds of the private placement for working capital purposes.

JMO

It appears their dumping what they can for cash to stay alive - $400,000 cash on hand May 31st, 2023 and now $205,000 for shares sold in placement makes $605,000 and burn rate a quarter is up to $1M now - All paid with more shares to insiders or Brokers doing placements with more shares

Here’s the latest MD&A

https://webfiles.thecse.com/Algernon_-_Financial_Statements_-_May_31_2023.pdf?3BDnofPUaIMafoRlE30llhlwsGG5Rhat

[shell3]

Condensed Interim Consolidated Financial Statements

https://webfiles.thecse.com/Algernon_-_Financial_Statements_-_May_31_2023.pdf?3BDnofPUaIMafoRlE30llhlwsGG5Rhat=